Go Pro
→ Analyst nicknamed “The Prophet” issues new warning for America (From Stansberry Research) (Ad)tc pixel
LON:HLN

Haleon Interim Earnings Report

Haleon logo
GBX 342.70 -2.20 (-0.64%)
As of 09/25/2026 12:05 PM Eastern
ProfileEarnings HistoryForecast

Haleon EPS Results

Actual EPS
GBX 8.60
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Haleon Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Haleon Announcement Details

Quarter
Interim
Date
7/30/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Haleon Earnings Headlines

Haleon Turns to Weight-Loss Drug Users for its Next U.S. Growth Opportunity
September 21, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/news/haleon-turns-to-weight-loss-drug-users-for-its-next-u-s-growth-opportunity-1841720/
Haleon is gaining from the side effects of weight-loss drugs
September 18, 2026  |  msn.comhttps://www.msn.com/en-us/news/money/haleon-is-gaining-from-the-side-effects-of-weight-loss-drugs/ar-AA2cxjUA
If you keep cash in a U.S. bank account… read this NOW
Since 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every dollar while paying savers just 0.04 percent interest. A new law, the GENIUS Act signed last summer, has cleared the way for a different kind of money to emerge this fall, one that could offer savings rates up to 6 percent. See what Ian King, Chief Strategist at Strategic Fortunes, has uncovered about this shift before it goes live.tc pixel
 |  Banyan Hill Publishing (Ad)
Haleon Discloses Director Share Purchase via Dividend Reinvestment
September 18, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/haleon-discloses-director-share-purchase-via-dividend-reinvestment?utm_source=marketbeat.com&utm_medium=referral
Advil-maker Haleon boosts US sales by targeting consumers on weight-loss drugs
September 16, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/advil-maker-haleon-boosts-us-sales-by-targeting-consumers-on-weight-loss-drugs/ar-AA2clx7e
Deutsche Bank Reaffirms Their Sell Rating on Haleon PLC (HLN)
September 10, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/HLN/pressreleases/4536460/deutsche-bank-reaffirms-their-sell-rating-on-haleon-plc-hln/
See More Haleon Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Haleon? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Haleon and other key companies, straight to your email.

About Haleon

Haleon (LON:HLN) (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

View Haleon Profile
Earnings Tools